Business
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc.
About this update from Hcw Biologics Inc.
[{"type":"text","content":"Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., April 13, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that data for the mechanism underlying HCW9218 against solid tumors will be presented at the 2023 Annual Meeting of the American Association for Cancer Research to be held in Orlando, Florida from April 14 – April 19, 2023. HCW9218 is an injectable, bifunctional fusion protein complex designed to simultaneously stimulate effector T cell and natural killer cell responses and inhibit the activity of TGF-β and its immunosuppressive effect. There are currently two ongoing clinical trials to evaluate HCW9218 in solid tumors. A Company-sponsored Phase 1b/2 clinical trial in patients with chemo-refractory/chemo-resistant pancreatic cancer currently has four clinical sites enrolling patients. The Masonic Cancer Center, University of Minnesota is sponsoring a Phase 1 study to evaluate HCW9218 in various solid tumors. The Company selected chemo-refractory/chemo-resistant solid tumors for its first clinical indications because solid tumor cancers are characterized by a dense fibrotic stroma or desmoplasia that allows a tumor to shield itself from standard-of-care treatment, such as chemotherapy and immune-checkpoint inhibitors. The immunosuppressive growth factor, TGF-β, plays a major role in formation of desmoplasia and promoting tumor growth and metastasis. Details of the presentation are as follows: Session Category:Clinical Research Excluding TrialsSession Title:Immunomodulatory Agents and InterventionsAbstract Title: Bifunctional immunotherapeutic HCW9218 facilitates recruitment of immune cells from tumor draining lymph nodes to promote antitumor activity and enhance checkpoint blockade efficacy in solid tumorsPresenter(s):Pallavi Chaturvedi, Ph.D. and Varghese George, Ph.D.Session Date and Time: Tuesday April 18, 2023 9:00 AM - 12:30 PM, EasternLocation:Poster Section 40Poster Board Number:27Published Abstract Number:4441 The poster presentation will be ma...